Skip to main content

Breast Cancer

Breast Cancer

Effect of Concomitant Treatment with Radiation Therapy and CDK4/6 in Patients with Advanced Breast Cancer

Breast Cancer

Recent Phase 2 Results for Lerociclib (G1T38), an Oral CDK4/6 Inhibitor Combined with Fulvestrant Used to Treat Patients with Advanced Breast Cancer

Breast Cancer

Management Strategies for Abemaciclib-Associated Diarrhea in Patients with Hormone Receptor–Positive, HER2-Negative Advanced Breast Cancer

Breast Cancer

Benefit of Alpelisib When Combined with Fulvestrant as Demonstrated Through Biomarker Subanalysis from the SOLAR-1 Study

Breast Cancer

Overall Survival Benefit with Ribociclib plus Endocrine Therapy in Patients with Hormone Receptor–Positive, HER2-Negative Advanced Breast Cancer: 4-Year Follow-Up Study of MONALEESA-7

Breast Cancer

BYLieve Study Results Support the Use of Alpelisib Combined with Fulvestrant for Hormone Receptor–Positive, HER2-Negative, PIK3CA Mutation–Positive Advanced Breast Cancer

Breast Cancer

PALOMA-3 Trial Shows Benefits to Overall Survival as Measured by Prognostic Indicators

Breast Cancer

Favorable Tolerability Profile of Sequential Radiation Therapy in Patients Receiving CDK4/6 Inhibitors for Metastatic Breast Cancer

Breast Cancer

Expanded Safety Analysis of the Phase 3b CompLEEment-1 Trial with Ribociclib plus Letrozole in Patients with Hormone Receptor–Positive, HER2-Negative Advanced Breast Cancer

Breast Cancer

A Network Meta-Analysis of Treatment-Related Adverse Events of Various CDK4/6 Inhibitors in Metastatic Breast Cancer

4
5
6
7
8
9
10

Page 7 of 11
Results 61 - 70 of 101